Why Are Generic Drugs in Shortage in 2026? The Economics, Explained

Active US drug shortages reached 227 in the second quarter of 2026, rising for the third straight quarter. That is still below the all-time high of 323 in early 2024, but the direction is wrong and the pattern is familiar. I spent a few weeks reading the pharmacist, economist, and industry reports to understand why this keeps happening. The short version: the shortages are not accidents. They are what this market is designed to produce.

The numbers right now

Central nervous system drugs are the largest shortage category, followed by antimicrobials, then chemotherapy and hormone agents. Contrast agents used in CT and MRI scans made up 10 percent of all new 2026 shortages, which means the problem reaches into diagnostics, not just treatment. And for 59 percent of 2025 shortages, manufacturers told the University of Utah's investigators the cause was "unknown" or declined to answer at all. That opacity is part of the story too.

The core problem: generics are too cheap to survive

This is the sentence that reframes everything: generic drugs are so cheap that manufacturers cannot afford to keep making them reliably.

Group purchasing organizations have pushed generic injectable prices so low that producers cannot justify the capital investment needed to sustain quality-control systems. When one plant has a contamination problem or shuts down for remediation, there is no backup, because backup capacity costs money that margins do not allow. The result is a market with no redundancy. One failure becomes a national shortage.

A 2025 Brookings analysis by Marta Wosińska and Rena Conti identified the mechanism precisely. Medicare pays the same price for a generic regardless of which manufacturer made it, so investments in reliability go unrewarded. Group purchasing contracts can lock in prices without guaranteeing volume. Hospitals switch suppliers for relatively small savings. Among generic sterile injectables approved between 2000 and 2011, just over 1 percent referenced more than one manufacturing facility, compared with nearly 20 percent of branded sterile injectables. The branded market builds backups. The generic market cannot afford to.

Sole-source fragility

Just under half of all new 2026 shortages involve sole-source products: a single manufacturer whose disruption eliminates the entire domestic supply with no immediate alternative. Five injectable drugs, atropine sulfate, cefotaxime, fentanyl citrate, epinephrine bitartrate, and lidocaine hydrochloride, have each been in shortage for more than a decade. According to United States Pharmacopeia data, all five depend on at least one key starting material manufactured in a single country, a vulnerability far upstream that finished-dose data does not reveal. Three of the five cost less than $3 per unit.

Think about that. Drugs that cost less than a cup of coffee, that hospitals cannot function without, and the economics say: do not bother building a second factory.

Why scarcity does not fix itself

In a functioning market, scarcity raises prices, new suppliers enter, and equilibrium returns. The generic sterile injectable market cannot do this. Prices are contracted, reimbursement is fixed, and entering production means building a sterile manufacturing facility for a product that sells for $3 a unit. The cavalry is not coming.

India supplies roughly 47 percent of US generic drug volume, adding geopolitical and shipping-route exposure on top of the domestic fragility. When platinum prices surged in 2025 and 2026, manufacturers of platinum-based chemotherapy drugs faced raw material costs that made government-fixed prices unviable, and production lines simply stopped.

What would actually help

The FDA flagged these structural vulnerabilities in a 2019 task force report, and most of the fixes require Congress, not regulators:

• Pay for reliability. Reimbursement that rewards manufacturers for maintaining backup capacity and quality systems, not just the lowest bid.
• Earlier notification. Stronger FDA authority to compel manufacturers to report planned discontinuations or interruptions before they cascade.
• Strategic reserves. Stockpiles of critical shortage-prone drugs, the way the country stockpiles other essentials.
• Multi-source incentives. Financial incentives for keeping more than one manufacturer producing essential medications.

None of this is mysterious. It is just expensive, and until someone pays for resilience, the patient is the one carrying the bag, as the Brookings researchers put it.

FAQs